| Project/Area Number |
07807070
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
TSUTAMOTO Takayoshi Shiga University of Medical Science, First Internal Medicine Assistant Professor, 医学部, 助手 (40197695)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Yoshihisa Shiga University of Medical Science First Internal Medicine Assistant Professor, 医学部, 助手 (30216337)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1996: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1995: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | congestive Heart failure / endothelin / atrial natriuretic peptide / cGMP / prognosis |
|---|
| Research Abstract |
Plasma levels of endothelin (ET) -1 and atrial natriuretic peptide (ANP) increase with the progression and the severity of congestive heart failure (CHF). ET-1 mediates vasoconstriction and myocardial hypertrophy. We demonstrated that high plasma ET-1 patients with CHF had a poor prognosis, suggesting the important role of ET-1 in CHF.As ANP inhibits ET-1 secretion in vitro, we evaluated whether endogenous ANP inhibit the ET-1 secretion in dogs with CHF by using specific ANP receptor antagonist (HS 142-1).
Our recent finding indicates that endogenous ANP directly inhibits endogenous ET-1 secretion through a cGMP-mediated path way in CHF.
|
